Tirzepatide The landscape of treatments for type 2 diabetes and obesity is rapidly evolving with the advent of non-peptide GLP-1 receptor agonists.(PDF) The development of non-peptide glucagon-like ... Unlike their traditional peptide-based counterparts, these novel small molecules offer promising advantages, including oral bioavailability and potentially improved patient convenience.2021年3月16日—Considerable progress has been made in discoveringnon-peptide agonists and positive allosteric modulators (PAMs) of GLP-1 receptorswith demonstrated efficacy. This new class of drugs represents a significant scientific advancement, aiming to mimic the beneficial effects of naturally occurring glucagon-like peptide-1 (GLP-1) without the inherent limitations of peptide structures, such as susceptibility to degradation in the gastrointestinal tract.
Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone that plays a crucial role in regulating blood glucose levels and appetite. GLP-1 receptor agonists (GLP-1RAs) are a class of medications designed to activate these receptors, thereby stimulating insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. Traditionally, these agonists have been peptides, mirroring the structure of the natural hormone. However, peptides are prone to enzymatic breakdown in the digestive system, necessitating injectable administration.作者：F Malik·2022·被引用次数：43—Considerable progress has been made in discoveringnon-peptide agonists and positive allosteric modulators (PAMs) of GLP-1 receptorswith demonstrated efficacy.
The development of non-peptide GLP-1 receptor agonists, often referred to as small-molecule agonists, represents a paradigm shift. These compounds are chemically synthesized molecules that can bind to and activate the GLP-1 receptor but are not peptides themselves. This non-peptide nature allows them to bypass the gastrointestinal degradation issues that plague peptide-based drugs, opening the door for oral administration. Drugs like orforglipron (also known as TT-OAD2 or LY3502970) are at the forefront of this development, demonstrating the potential for once-daily oral dosing. Researchers are also exploring non-peptide positive allosteric modulators (PAMs) of GLP-1 receptors, which can enhance the receptor's response to endogenous GLP-1Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide ... - PMC.
The transition from injectable peptide GLP-1s to oral non-peptide agents offers several compelling advantages. The most significant is the elimination of the need for injections, which can be a barrier for some patients due to needle phobia, inconvenience, or the need for cold storage作者：TF Martinez·2020·被引用次数：8—GLP-1 causes a rapid change in the conformation of Gs, while TT-OAD2 results in a much slower change in the conformation of Gs. These .... Oral administration, as exemplified by orforglipron, significantly enhances patient convenience and adherence to treatment regimens.
Furthermore, non-peptide molecules may avoid certain gastrointestinal (GI) degradation barriers that limit the efficacy and absorption of peptides. This improved oral bioavailability can lead to more consistent drug exposure and potentially a more predictable therapeutic effect. While both peptide and non-peptide GLP-1 agonists are effective in treating type 2 diabetes and obesity, the oral route offered by non-peptide options represents a substantial leap in patient-centric drug development.
Orforglipron has emerged as a leading candidate in the non-peptide GLP-1 agonist space. Clinical trials, including Phase 3 studies, have demonstrated its efficacy in lowering A1C levels and promoting weight loss, positioning it as a potential competitor to established injectable GLP-1s like semaglutide and tirzepatide.GLP-1RAs may trigger chronic cough for some patients with ... Research into orforglipron highlights its design to overcome the intrinsic limitations of peptides, aiming for effective once-daily oral administration.
Beyond orforglipron, other research efforts are focused on discovering and developing novel non-peptide agonists and allosteric modulators. These studies often involve computational screening of natural product databases and structure-based drug design to identify compounds that can effectively interact with the GLP-1 receptor. While these agents show demonstrated efficacy, ongoing research also investigates potential side effects, such as gastrointestinal issues like nausea, which have been observed with GLP-1 therapies in general.
The development of non-peptide GLP-1 receptor agonists marks a significant milestone in the ongoing effort to find more effective and convenient treatments for metabolic disorders. As these novel oral therapies progress through clinical development and potentially gain regulatory approval, they promise to expand treatment options for millions of individuals living with type 2 diabetes and obesity. The shift towards small-molecule, orally administered GLP-1RAs underscores a commitment to improving patient outcomes through innovative drug design that prioritizes both efficacy and ease of use. This evolving field continues to explore the intricate mechanisms of GLP-1 receptor activation, seeking to harness its therapeutic potential in new and accessible ways.作者：X Zhang·2020·被引用次数：215—Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by thenon-peptideagonist ...
Join the newsletter to receive news, updates, new products and freebies in your inbox.